Your session is about to expire
← Back to Search
Behavioral Intervention
Technology-Assisted Conscientiousness Therapy for Multiple Sclerosis (TACT-MS Trial)
N/A
Waitlist Available
Research Sponsored by State University of New York at Buffalo
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline only
Awards & highlights
Summary
This trial tests a phone app called 'Conscientiousness-Coach' designed to help people manage their health and work better. It targets people with Multiple Sclerosis who have low conscientiousness and includes healthy individuals over 60 for comparison. The app uses cognitive-behavioral techniques to help users become more organized and responsible.
Who is the study for?
This trial is for adults over 18 with Multiple Sclerosis (MS) who are currently working and have a low score on the NEO-FFI Conscientiousness test, indicating less conscientious behavior than average. People with substance abuse issues, psychiatric disorders, or neurological diseases other than MS cannot participate.
What is being tested?
The study is testing a phone app designed to improve health management and work life for people with MS by boosting their conscientiousness—a personality trait linked to responsible and organized behavior.
What are the potential side effects?
Since this intervention involves using an app rather than medication, traditional side effects are not expected. However, users may experience stress or frustration if they find it challenging to engage with the technology or adhere to its recommendations.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at baseline only
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at baseline only
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Buffalo Vocational Monitoring Survey (BVMS): change from baseline to 12 weeks and from baseline to 24 weeks
Self -Reflection and Insight Scale (SRIS): change from baseline to 12 weeks and from baseline to 24 weeks
The Valued Living Questionnaire (VLQ): change from baseline to 12 weeks and from baseline to 24 weeks
Secondary study objectives
Beck Anxiety Inventory (BAI): change from baseline to 12 weeks and from baseline to 24 weeks
Beck Depression Inventory 2nd Edition (BDI-II): change from baseline to 12 weeks and from baseline to 24 weeks
Multiple Sclerosis
+5 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
Group II: Waitlist ControlActive Control1 Intervention
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Multiple Sclerosis (MS) include immunomodulatory drugs that modulate the immune system to reduce relapse frequency and severity, and non-pharmacologic approaches like physiotherapy and mindfulness-based interventions that improve mobility, mood, and quality of life. The Conscientiousness-Based Phone App likely enhances self-management and adherence to treatment plans through behavioral interventions, which is crucial for MS patients as it can lead to better disease management, reduced symptom severity, and improved daily functioning.
Best Methods of Communicating Clinical Trial Data to Improve Understanding of Treatments for Patients with Multiple Sclerosis.
Best Methods of Communicating Clinical Trial Data to Improve Understanding of Treatments for Patients with Multiple Sclerosis.
Find a Location
Who is running the clinical trial?
State University of New York at BuffaloLead Sponsor
267 Previous Clinical Trials
52,375 Total Patients Enrolled
12 Trials studying Multiple Sclerosis
3,266 Patients Enrolled for Multiple Sclerosis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have been diagnosed with Multiple Sclerosis.Your score for conscientiousness on the NEO-FFI test is much lower than the average score for healthy adults.Your score for conscientiousness on the NEO-FFI test is higher than 40.You are currently employed full- or part-time.You are above 18 years of age.\nYou have been diagnosed with Multiple Sclerosis.
Research Study Groups:
This trial has the following groups:- Group 1: Intervention
- Group 2: Waitlist Control
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Multiple Sclerosis Patient Testimony for trial: Trial Name: NCT04953689 — N/A
Share this study with friends
Copy Link
Messenger